Table I.
Univariate analysis of overall survival after the diagnosis of unresectable CRLM.
| Overall survival | |||
|---|---|---|---|
|
|
|||
| Factor | N | Median (years) | P-value |
| Age (years) | |||
| <60 | 10 | 1.18 | 0.8451 |
| ≥60 | 30 | 0.66 | |
| Gender | |||
| Male | 30 | 1.18 | 0.7956 |
| Female | 10 | 0.74 | |
| Timing of tumor | |||
| Synchronous | 26 | 0.74 | 0.0853 |
| Metachronous | 14 | 1.65 | |
| Primary site | |||
| Colon | 23 | 1.46 | 0.5902 |
| Rectum | 17 | 0.90 | |
| Primary tumor resection | |||
| Yes | 32 | 1.43 | 0.0161 |
| No | 8 | 0.48 | |
| Primary tumor stage | |||
| II,III | 11 | 1.59 | 0.1227 |
| IV | 29 | 0.78 | |
| Extrahepatic disease | |||
| Yes | 24 | 1.10 | 0.4308 |
| No | 16 | 0.88 | |
| Chemotherapy for CRLM | |||
| Yes | 34 | 1.18 | 0.0119 |
| No | 6 | 0.51 | |
| Serum CEA (ng/ml) | |||
| <100 | 22 | 1.55 | 0.0148 |
| ≥100 | 18 | 0.62 | |
| Serum CA19-9 (U/ml) | |||
| <100 | 30 | 1.55 | <0.0001 |
| ≥100 | 10 | 0.62 | |
| GPS | |||
| 0,1 | 33 | 1.28 | 0.0362 |
| 2 | 7 | 0.33 | |
CRLM, colorectal cancer liver metastases; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.